glp-1 agonist oral Orforglipron, an Small-Molecule Receptor for Obesity November 5, 2025 DOI: 10.1056/NEJMdo008238 New for the treatment of obesity - and so many additional indications being studied Evolution of GLP‐1 Receptor Agonists

The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes

Discover clinical trial results and which GLP-1 medication may be right for you.

Discover how microdosing GLP-1s can have low side effects, low costs, and support weight loss

Amgens MariTide leads the GLP-1 obesity therapy market in 2025 with innovative design, Phase-3 trials, and strong potential for effective weight loss.

You can wear multiple PatchAid patches at the same time

Their findings suggest that patients may be able to continue taking the medications prior to their surgeries without a high risk of aspiration.As more patients begin taking medications to help manage blood sugar l